Integer Holdings Corporation logo

Integer Holdings Corporation

ITGR

NYSEHealthcareMedical - Devices

Latest quote

$125.19

−$0.01 · -0.01%

Aug 21, 3:55 PM ET

ITGR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

92

Deep Value

Momentum

46

Neutral

Sentiment

68

Bullish

Risk resilience

70

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Payman Khales
Listed since
Sep 29, 2000
Employees
11,000

Market position

Volume
614.24K
0.78× average
Average volume
791.19K
Average daily volume
Market cap
4.25B USD
Beta
0.61
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.11B USD
P/E (TTM)
33.93×
P/B (TTM)
2.48×
P/S (TTM)
2.31×
EV / EBITDA
13.98×
Earnings yield
3.77%
Free cash flow yield
3.86%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
23.73%
Operating margin
9.47%
Net margin
6.97%
Return on equity
5.88%
Return on assets
3.01%
Return on invested capital
5.36%

Financial health

Debt / equity
0.79×
Current ratio
3.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends30%21%12%3%Gross margin, FY2021: 27.60%Gross margin, FY2022: 26.04%Gross margin, FY2023: 26.45%Gross margin, FY2024: 26.87%Gross margin, FY2025: 23.06%Operating margin, FY2021: 11.11%Operating margin, FY2022: 8.46%Operating margin, FY2023: 10.50%Operating margin, FY2024: 12.13%Operating margin, FY2025: 11.33%Net margin, FY2021: 7.93%Net margin, FY2022: 4.99%Net margin, FY2023: 5.83%Net margin, FY2024: 6.98%Net margin, FY2025: 5.57%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.60%. Gross margin FY2022 26.04%. Gross margin FY2023 26.45%. Gross margin FY2024 26.87%. Gross margin FY2025 23.06%. Operating margin FY2021 11.11%. Operating margin FY2022 8.46%. Operating margin FY2023 10.50%. Operating margin FY2024 12.13%. Operating margin FY2025 11.33%. Net margin FY2021 7.93%. Net margin FY2022 4.99%. Net margin FY2023 5.83%. Net margin FY2024 6.98%. Net margin FY2025 5.57%.

Income trends

Revenue

1.85B USD+7.57%

Operating income

209.27M USD+0.49%

Net income

102.76M USD-14.29%
Income trends across reported periods2.02B USD1.31B USD600.4M USD−111.63M USDRevenue, FY2021: 1.22B USDRevenue, FY2022: 1.33B USDRevenue, FY2023: 1.56B USDRevenue, FY2024: 1.72B USDRevenue, FY2025: 1.85B USDOperating income, FY2021: 135.71M USDOperating income, FY2022: 112.68M USDOperating income, FY2023: 163.32M USDOperating income, FY2024: 208.24M USDOperating income, FY2025: 209.27M USDNet income, FY2021: 96.81M USDNet income, FY2022: 66.38M USDNet income, FY2023: 90.65M USDNet income, FY2024: 119.9M USDNet income, FY2025: 102.76M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.22B USD. Revenue FY2022 1.33B USD. Revenue FY2023 1.56B USD. Revenue FY2024 1.72B USD. Revenue FY2025 1.85B USD. Operating income FY2021 135.71M USD. Operating income FY2022 112.68M USD. Operating income FY2023 163.32M USD. Operating income FY2024 208.24M USD. Operating income FY2025 209.27M USD. Net income FY2021 96.81M USD. Net income FY2022 66.38M USD. Net income FY2023 90.65M USD. Net income FY2024 119.9M USD. Net income FY2025 102.76M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.85B USD1.72B USD1.56B USD1.33B USD1.22B USD
Cost of goods sold1.42B USD1.26B USD1.14B USD984.63M USD884.11M USD
Gross profit425.81M USD461.18M USD411.52M USD346.65M USD336.97M USD
Research and development46.35M USD53.43M USD61.97M USD59.76M USD51.99M USD
Selling, general, and administrative162.59M USD184.33M USD171.47M USD157.36M USD141.69M USD
Operating expenses216.55M USD252.95M USD248.2M USD233.97M USD201.26M USD
Interest expense42.31M USD56.37M USD53.37M USD37.27M USD31.63M USD
Depreciation and amortization125.95M USD109.71M USD96.99M USD90.9M USD81.59M USD
Operating income209.27M USD208.24M USD163.32M USD112.68M USD135.71M USD
Net income102.76M USD119.9M USD90.65M USD66.38M USD96.81M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$118.25

5.55% downside
Past 12 months12-month forecastHigh $127Average $118.25Low $104

ITGR peers

ETFs holding ITGR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ITGR

research.disclaimer